Systematic review of dasatinib in chronic myeloid leukemia

Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic myeloid leukemia (CML) patients in chronic, accelerated, or blast phase with resistance or intolerance to imatinib therapy, for newly diagnosed chronic phase patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Breccia, Massimo, Salaroli, Adriano, Molica, Matteo, Alimena, Giuliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615898/
https://www.ncbi.nlm.nih.gov/pubmed/23569389
http://dx.doi.org/10.2147/OTT.S35360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615898/
https://www.ncbi.nlm.nih.gov/pubmed/23569389
http://dx.doi.org/10.2147/OTT.S35360

Ejemplares similares